Navigation Links
Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Date:10/30/2012

SAN DIEGO, Oct. 30, 2012 /PRNewswire/ -- Thesan Pharmaceuticals announced the closing of a $16M Series A financing, co-led by Novo Ventures and Novartis Venture Funds.  The company will focus on the development of novel approaches for the treatment of dermatological disorders. The lead drug candidate is a topically-applied new chemical entity expected to enter the clinic in 2013.

"For many years, drug development in the dermatology field has been dominated by old drugs just re-formulated into more cosmetically appealing foams, gels or lotions," said Gordon Foulkes, Thesan's Executive Chairman and CEO. "Thesan's mission is to develop new chemical entities with novel mechanisms of action in order to substantially improve treatment outcomes for patients with a variety of dermatological diseases." 

The company's first products have been licensed from the University of California, Irvine (UCI). The products have been developed in the laboratory of Professor Daniele Piomelli, who is Louise Turner Arnold Chair of Neurosciences at UCI and the Director of Drug Discovery and Development at the Istituto Italiano di Tecnologia (IIT), Genoa, Italy.  

"We are very pleased to be part of the investor syndicate behind Thesan," said Peter Bisgaard, Partner at Novo Ventures. "We believe Professor Piomelli's work offers a unique opportunity for developing a completely new class of anti-inflammatory agents, which can be moved rapidly into clinical development. Further, we look forward to working with Professor Piomelli and Thesan management to build the pipeline of future candidates."

"This is an extremely exciting opportunity to move toward the clinic the first technology born from the long-standing international collaboration between UCI and the IIT," said Professor Piomelli. "Our collaboration to develop therapeutic candidates has been validated by our ability to attract such a strong management team and group of investors
'/>"/>

SOURCE Thesan Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant Pharmaceuticals Reschedules Its Third Quarter 2012 Financial Results Webcast And Conference Call To November 2, 2012 Due To Hurricane Sandy
2. Neuraltus Pharmaceuticals Announces Phase 2 Clinical Results for NP001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
3. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
4. Jazz Pharmaceuticals Announces Date to Release Third Quarter 2012 Results
5. Watson Announces Sale of Rugby OTC Product Trademark and Assets to Major Pharmaceuticals, a division of The Harvard Drug Group, LLC
6. Del Mar Pharmaceuticals Expands Collaboration with Guangxi Wuzhou Pharmaceutical Company
7. Webcast Alert: Isis Pharmaceuticals Third Quarter 2012 Financial Results Conference Call
8. BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
9. Access Pharmaceuticals Announces Private Placement Financing
10. Desitin Pharmaceuticals selecciona Veeva CRM, solución basada en la nube
11. Desitin Pharmaceuticals entscheidet sich für das cloudbasierte Veeva CRM zur Unterstützung seiner Expansion auf den britischen Markt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  Hill-Rom (NYSE: ... Providence Health ( Renton, WA ), the ... expands the companies, existing relationship as Hill-Rom now becomes ... Bariatric capital bed frame and surface products. ... systems in the U.S.  It operates 34 hospitals, 475 ...
(Date:9/23/2014)... Sept. 23, 2014  MEDIMETRIKS PHARMACEUTICALS today announced ... Resnick have been elected to Medimetriks, Board ... Mr. Lary, who will serve on Medimetriks, Audit ... experience to the Company.  Mr. Lary is currently ... a leading institutional investment firm.  Mr. Lary is ...
(Date:9/23/2014)... Sept. 23, 2014   COTA, Inc. today ... $7 million Series A funding round led by Horizon ... is the first big data platform designed by practicing ... analysis for cancer care in support of healthcare,s new ... to expand development of the COTA platform, hire biostatisticians, ...
Breaking Medicine Technology:Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... MARINO, Calif. March 25, 2011 VG Energy, ... VRAL ), announced today that it ... to verify lab results on a large scale for the development ... VG Energy has developed proprietary technology, with results ...
... Ltd. (Nasdaq: SVA ), a leading provider ... Weidong Yin, President and CEO, and Ms. Helen Yang, ... UBS Greater China Healthcare Corporate Day.  The conference will ... March 28th to March 29.  The Sinovac team will ...
Cached Medicine Technology:VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 2VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 3VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 4Sinovac Participates in UBS Greater China Healthcare Corporate Day 2
(Date:9/23/2014)... (PRWEB) September 23, 2014 Mel Frank, ... about cultivating, growing and harvesting marijuana. He is perhaps ... the field and he’ll be leading a special elective ... am to 5:00 pm at Oaksterdam University ... law, botany and nomenclature, harvesting and manicuring, and identifying ...
(Date:9/23/2014)... that FDG-PET technology is less accurate in diagnosing ... infections like histoplasmosis or tuberculosis are common. ... lead to unnecessary tests and surgeries for patients, ... Histoplasmosis and other fungal diseases are linked to ... and are found in soils. , The study ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
(Date:9/23/2014)... 2014 (HealthDay News) -- A test used to diagnose lung ... certain lung infections are more common, a new analysis says. ... through the use of what,s known as functional imaging. For ... is used, according to the study authors. Cancerous tumors ... parts of the lungs that don,t have cancer, according to ...
(Date:9/23/2014)... 23, 2014 Grinnell Mutual seeks ... projects in the Midwest. Working Together Making It ... non-profit organizations with projects positively impacting their communities. ... marketplace make their communities a better places,” said ... Community Relations Barb Baker. “Their leadership—as coaches, as ...
Breaking Medicine News(10 mins):Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2
... death rates, longer hospital stays and greater costs , , ... (GI) bleeding admitted to hospitals on weekends are more ... to two studies that analyzed U.S. patient data. ... upper gastrointestinal hemorrhage (NVUGIH) admitted on weekends were 36 ...
... of Your Mental Health Talk Radio www.blogtalkradio.com/yourmentalhealth when ... Men Are From Mars, Women Are From Venus ... new book When Mars and Venus Collide: Improving Relationships ... on Thursday, March 5th at 8 PM EST/5 PM ...
... Hit Unprecedented Lows; Approximately Half of Hospitals UnprofitableANN ... margin of U.S. hospitals has fallen to zero ... hospital finances published today. Driven largely by ... apparent in all types of hospitals - small, ...
... than 52,000 patients from eight countries has shown that ... improvements and greater patient satisfaction. , The findings, ... International Journal of Clinical Practice , show that 53 ... less than seven per cent, the target set by ...
... users with Zix CorporationDALLAS, March 2 Zix Corporation ... Blue Shield of Massachusetts (BCBSMA) today announced a contract ... Zix Corporation and Blue Cross Blue Shield of Massachusetts ... entering its sixth year. Under the contract terms, ...
... Edwin Ishoo , MD, an Otolaryngologist and facial ... the use of both minimally invasive and non-invasive techniques ... procedures implemented by Dr. Ishoo are also designed to ... activities as soon as possible."We are committed to using ...
Cached Medicine News:Health News:Weekend Admission May Be Riskier for GI Bleeding 2Health News:John Gray Will Discuss His New Book Why Mars and Venus Collide 2Health News:Thomson Reuters Study Tracks Impact of Recession on Hospitals 2Health News:Thomson Reuters Study Tracks Impact of Recession on Hospitals 3Health News:Insulin drug study shows significant improvements in more than 52,000 diabetic patients 2Health News:Insulin drug study shows significant improvements in more than 52,000 diabetic patients 3Health News:Zix Corporation and Blue Cross Blue Shield of Massachusetts Expand the Industry's Largest e-Prescribing Program 2Health News:Edwin Ishoo MD Providing Non-Invasive Cosmetic Procedures, Minimizing Recovery Time 2
... 210, Carl Zeiss has created a surgical microscope ... for ophthalmic surgery. Its wide range of uses ... and it offers new functions to improve depth ... integrated assistant's microscope the OPMI VISU 210 is ...
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
MONOJECT Brown Stopper...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
Medicine Products: